Description: Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 µM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR, and KDR. Target: c-Kit, CSF-1R, Src, FLT, PDGFR, Apoptosis....

Tandutinib is a potent antagonist of platelet-derived growth factor receptor beta (PDGFRbeta), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine...

Tandutinib (also known as MLN518 or CT53518) is an orally active inhibitor of Fms-like tyrosine kinase 3 (FLT3) kinase, PDGFRb and c-Kit. It inhibits FLT3 phosphorylation, downstream signaling and tumor growth in vitro and in animal models. Solubility: Soluble in DMSO at 25mg/ml with slight warming, soluble in...

A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases.

Soluble in DMSO or ethanol. Tandutinib inhibits the auto-phosphorylation of FLT3 (FMS-Like Tyrosine kinase-3, IC(50) of 0.22µM), c-KIT and PDGF (platelet-derived growth factor), thereby inhibiting cellular proliferation and inducing apoptosis. Target: PDGFR , Kinase Group: RTK , Substrate: Tyrosine